ReviewFrontiers in neurology2018
Tau Filaments and the Development of Positron Emission Tomography Tracers.
Review in Frontiers in neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- Diagnostic and therapeutic targeting of pathological tau proteins in neurodegenerative disorders.FEBS open bio · 2024Review
- Novel aspects of the phosphorylation and structure of pathological tau: implications for tauopathy biomarkers.FEBS open bio · 2024Review
- Insight into the Binding of First- and Second-Generation PET Tracers to 4R and 3R/4R Tau Protofibrils.ACS chemical neuroscience · 2023Article
- In vitro evidence for a nonselective 4R tau PET tracer.Molecular psychiatry · 2023Article
- 18F-MK-6240 tau-PET in genetic frontotemporal dementia.Brain : a journal of neurology · 2022Article
- Imaging Clinical Subtypes and Associated Brain Networks in Alzheimer's Disease.Brain sciences · 2022Review
- Tau mRNA Metabolism in Neurodegenerative Diseases: A Tangle Journey.Biomedicines · 2022Review
- Dissecting the Binding Profile of PET Tracers to Corticobasal Degeneration Tau Fibrils.ACS chemical neuroscience · 2021Article
- Cryptic Sites in Tau Fibrils Explain the Preferential Binding of the AV-1451 PET Tracer toward Alzheimer's Tauopathy.ACS chemical neuroscience · 2021Article
- Synthesis and Assessment of Novel Probes for Imaging Tau Pathology in Transgenic Mouse and Rat Models.ACS chemical neuroscience · 2021Article
- Cryo-EM structures of tau filaments from Alzheimer's disease with PET ligand APN-1607.Acta neuropathologica · 2021Article
- Development and evaluation of [Synapse (New York, N.Y.) · 2021Article
- Pick's Tau Fibril Shows Multiple Distinct PET Probe Binding Sites: Insights from Computational Modelling.International journal of molecular sciences · 2020Article
- A fluorescent molecular imaging probe with selectivity for soluble tau aggregated protein.Chemical science · 2020Article
- Precision Medicine for Frontotemporal Dementia.Frontiers in psychiatry · 2019Review
- Frontrunner in Translation: Progressive Supranuclear Palsy.Frontiers in neurology · 2019Review
- Detection of tau in Gerstmann-Sträussler-Scheinker disease (PRNP F198S) by [Acta neuropathologica communications · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
A pathological pathway leading from soluble, monomeric to insoluble, filamentous Tau, is believed to underlie human Tauopathies. Cases of frontotemporal dementia are caused by dominantly inherited mutations in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.